We began developing Melaseq, the worlds first non-invasive cancer biomarker in 2016, after years of research in cancer genomics and assay development.
Click to view an annotated timeline of our Melaseq development progress and company milestones.
Third Melaseq validation study published in PLOS ONE
Partnership with Australian Clinical Labs
Geneseq Biosciences and Australian Clinical Labs today announced they will partner to bring the first non-invasive melanoma test to market under the trademark Melaseq™. Clinical Labs is the largest pathology provider to public hospitals in Australia, with over 90 NATA accredited laboratories and 900 collection sites nation-wide.
Accepted to Melbourne Health Accelerator Spring 2017 Cohort
Geneseq Biosciences invited to participate in Australia’s first hospital ‘in-situ’ accelerator program, in association with Health Round Table. The MHx program provides innovative start-up companies with the opportunity to access the world-class Royal Melbourne Hospital health system and empowers clinicians and researchers to pursue an entrepreneurial mindset within a structured collaborative framework.